Want to see TSE:BUX full AI Analyst Report?
BUX Stock Chart & Stats
C$0.46
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.46
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.27 - C$0.64
Previous CloseN/A
Volume0.00
Average Volume (3M)16.46K
Market Cap
C$56.75M
Enterprise ValueC$58.02M
Total Cash (Recent Filing)C$1.29M
Total Debt (Recent Filing)C$711.78K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)13.22
Price to Sales (P/S)149.23
P/FCF Ratio-20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostics BusinessBioMark operates in a durable, high-barrier niche: blood-based diagnostics and biomarker discovery for early disease detection. This business model, if clinically validated, can create recurring revenue streams and strong clinical/IP moats that sustain growth over multiple years.
Moderate Current LeverageReported debt levels are modest relative to many peers, implying less immediate solvency pressure and some runway to pursue validation or commercialization. Moderate leverage reduces near-term refinancing strain and preserves flexibility while working toward revenue scale.
Signs Of Past Revenue ImprovementAlthough current sales are small, prior periods showed revenue gains, indicating the company can convert R&D into commercial activity. This operational capability suggests commercialization momentum that, if sustained, supports longer-term scaling and improved operating leverage.
Bears Say
Very Small, Declining RevenueA tiny and falling revenue base undermines economies of scale and delays margin expansion; it constrains reinvestment capacity and increases dependence on external funding. Sustained top-line weakness makes it harder to achieve profitable, self-funded growth.
Persistent Negative Cash FlowMaterial and ongoing cash burn requires recurrent financing to cover operations and development. This pressure increases dilution and diverts management focus to fundraising, limiting ability to fund clinical validation, commercialization, or hire key personnel for long-term growth.
Deep Losses & Balance-sheet VolatilityDeeply negative margins (TTM net margin ~-13x revenue) plus past balance-sheet instability raise financing and dilution risk. Persistent losses hinder reinvestment, weaken partner confidence, and make the firm vulnerable to adverse funding conditions over the medium term.
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.27 and its highest was C$0.64 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$56.75M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Jul 15, 2026 which is in 8 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Mar 02, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 105,090,210 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---